Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: For patients who have a ventricular tachyarrhythmic event, implantable cardioverter-defibrillators (ICDs) are a mainstay of therapy to prevent sudden death. However, ICD shocks are painful, can result in clinical depression, and do not offer complete protection against death from arrhythmia. We designed this randomized trial to examine whether prophylactic radiofrequency catheter ablation of arrhythmogenic ventricular tissue would reduce the incidence of ICD therapy. METHODS: Eligible patients with a history of a myocardial infarction underwent defibrillator implantation for spontaneous ventricular tachycardia or fibrillation. The patients did not receive antiarrhythmic drugs. Patients were randomly assigned to defibrillator implantation alone or defibrillator implantation with adjunctive catheter ablation (64 patients in each group). Ablation was performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary end point was survival free from any appropriate ICD therapy. RESULTS: The mortality rate 30 days after ablation was zero, and there were no significant changes in ventricular function or functional class during the mean (+/-SD) follow-up period of 22.5+/-5.5 months. Twenty-one patients assigned to defibrillator implantation alone (33%) and eight patients assigned to defibrillator implantation plus ablation (12%) received appropriate ICD therapy (antitachycardia pacing or shocks) (hazard ratio in the ablation group, 0.35; 95% confidence interval, 0.15 to 0.78, P=0.007). Among these patients, 20 in the control group (31%) and 6 in the ablation group (9%) received shocks (P=0.003). Mortality was not increased in the group assigned to ablation as compared with the control group (9% vs. 17%, P=0.29). CONCLUSIONS: In this randomized trial, prophylactic substrate-based catheter ablation reduced the incidence of ICD therapy in patients with a history of myocardial infarction who received ICDs for the secondary prevention of sudden death. (Current Controlled Trials number, ISRCTN62488166 [controlled-trials.com].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) trial, 30 which randomly assigned 128 ICD patients with a history of ventricular arrhythmia and myocardial infarction to ablation or usual care, arrhythmia recurrence was significantly decreased from 33% to 12% with ablation.”
From Managing with pacemakers and implantable cardioverter defibrillators (2013) · cites this paper as [30]
Citations
Cites
(1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372202 · Cited by 3,232
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction
Hohnloser, S. H., Kuck, K. H., Dorian, P., Roberts, R. S., Hampton, J. R., Hatala, R., Fain, E., Gent, M., & Connolly, S. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041489 · Cited by 1,519
Marchlinski, F. E., Callans, D. J., Gottlieb, C. D., & Zado, E. (2000) · Circulation · doi:10.1161/01.cir.101.11.1288 · Cited by 1,220
Moss, A. J., Greenberg, H., Case, R. B., Zareba, W., Hall, W. J., Brown, M. W., Daubert, J. P., McNitt, S., Andrews, M. L., & Elkin, A. D. (2004) · Circulation · doi:10.1161/01.cir.0000150390.04704.b7 · Cited by 597
Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol
Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., & Prystowsky, E. N. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402402 · Cited by 422
Guiraudon, G., Fontaine, G., Frank, R., Escande, G., Etievent, P., & Cabrol, C. (1978) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(10)62923-2 · Cited by 404
Electrical storm in patients with transvenous implantable cardioverter-defibrillators
Credner, S. C., Klingenheben, T., Mauss, O., Sticherling, C., & Hohnloser, S. H. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00495-1 · Cited by 376
Arenal, A., Glez-Torrecilla, E., Ortiz, M., Villacastín, J., Fdez-Portales, J., Sousa, E., del Castillo, S., Perez de Isla, L., Jimenez, J., & Almendral, J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02623-2 · Cited by 343
Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies
Goldberger, Z., & Lampert, R. (2006) · JAMA · doi:10.1001/jama.295.7.809 · Cited by 271
Research works printed but not linked: 1
- Stevenson WG, 2005, Curr Opin Cardiol, 20, 42
Cited by
Items 501–600 of 964
Komatsu, Y. (2014) · Journal of Arrhythmia · doi:10.1016/j.joa.2014.04.014 · Cited by 6
“Catheter ablation is an effective therapeutic option in the management of scar-related VT [11,12].”
BackgroundNair, G. M., Nery, P. B., Redpath, C. J., & Birnie, D. H. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000035 · Cited by 6
Enriquez, A. A., Neira, V., Bakker, D., Baley, J., Bisleri, G., Baranchuk, A. M., & Redfearn, D. (2019) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2019.06.002 · Cited by 6
Catheter ablation of scar based ventricular tachycardia – Procedural characteristics and outcomes
Yadav, A., Ramasamy, S., Theodore, J., Anantharaj, A., Pillai, A. A., Satheesh, S., & Selvaraj, R. J. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.09.009 · Cited by 6
(2009) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2009001400001 · Cited by 7
Clinical applications of image fusion for electrophysiology procedures
Rhode, K., Ma, Y., Housden, R. J., Karim, R., Rinaldi, C. A., Cooklin, M., Gill, J. S., O'Neill, M. D., Schaeffter, T., Relan, J., et al. (2012) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi.2012.6235840 · Cited by 6
Ventricular Arrhythmias in Patients With Implanted Cardioverter Defibrillators
John, R. M., & Stevenson, W. G. (2012) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.07.015 · Cited by 6
“In experienced centers, catheter ablation is now an early consideration in the course of management of recurrent monomorphic VT to avoid exposing patients to toxic drugs and risking multiple ICD shocks with associated posttraumatic stress disorder (Kuck et al. 2010, Reddy et al. 2007).”
BackgroundA Surgical Option for Ventricular Tachycardia Caused by Nonischemic Cardiomyopathy
Stevenson, W. G., & Couper, G. S. (2011) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.964189 · Cited by 6
The year in arrhythmias—2007: Part I
Josephson, M. E., Rosen, M. R., & Tomaselli, G. F. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.03.012 · Cited by 6
Self-citationMoser, F., Maslova, V., Zaman, A., Demming, T., Spehlmann, M. E., Saad, M. F., Frank, D., & Lyan, E. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.70018 · Cited by 5
Alzand, B. S. N., Timmermans, C. C., Wellens, H. J. J., Dennert, R. M., Philippens, S., Portegijs, P. J. M., & Rodriguez, L. (2011) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-011-9549-1 · Cited by 5
“As shown in different studies [17, 30], the beneficial effect of catheter ablation in the patient with frequent ICD interventions is obvious, but an important question remains unanswered: Should every patient with VT(s), an old myocardial infarction, and an ICD undergo a substrate modification using the voltage mappin…”
BackgroundNakahara, S. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.09.008 · Cited by 5
Sex and Gender Differences in Ventricular Arrhythmias
Warnock, R. K., Modi, R. D., & Westerman, S. B. (2023) · US Cardiology Review · doi:10.15420/usc.2022.38 · Cited by 5
Radiofrequency Ablation to Prevent Sudden Cardiac Death
Atoui, M., Gunda, S., Lakkireddy, D., & Mahapatra, S. (2015) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-11-2-121 · Cited by 5
Primary Ablation for Ventricular Tachycardia: When and How?
Santangeli, P., Biase, L. D., Al‐Ahmad, A., Hsia, H. H., Burkhardt, J. D., Sánchez, J., Bai, R., Casella, M., Russo, A. D., Tondo, C., et al. (2011) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2011.08.014 · Cited by 5
Hsieh, C. H. C., Chia, E.-M., Huang, K., Lu, J., Barry, M. A., Pouliopoulos, J., Ross, D. L., Thomas, S. P., & Kovoor, P. (2013) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.113.000447 · Cited by 5
“ICD implantation combined with prophylactic catheter ablation remote from the infarct (8–13 years) has been found to reduce the incidence of ICD-delivered therapy.(5,6) Our hypothesis is that RFA of inducible VT and its substrate early after an infarct would abolish or diminish late ventricular tachyarrhythmias.”
BackgroundMethodChiba, S., Abe, M., Nakamura, K., & Uehara, H. (2023) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytad379 · Cited by 5
“Mapping from the endocardial surface showed no mid-diastolic potential around the VT. Radiofrequency catheter ablation therapy was performed at the targeted site, resulting in transient termination of VT.”
BackgroundInfluentialFalzone, P. V., Vázquez‐Calvo, S., & Roca‐Luque, I. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00656-y · Cited by 5
Epicardial Ventricular Tachycardia Ablation for Which Patients?
Roten, L., Sacher, F., Daly, M. G., Pascale, P., Komatsu, Y., Ramoul, K., Scherr, D., Chaumeil, A., Shah, A. J., Denis, A., et al. (2012) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2012.1.39 · Cited by 6
Fujita, J., & Sano, M. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.04.002 · Cited by 5
Mapping and ablation procedures for the treatment of ventricular tachycardia
Killu, A. M., Mulpuru, S. K., & Asirvatham, S. J. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1186541 · Cited by 5
“have assessed the effect of VT ablation in ICM, only two were randomized [81,82] assessing the effect of VT ablation as an initial”
MethodProphylactic Catheter Ablation for Ventricular Tachycardia: Are We There Yet?
Mukherjee, R. K., O’Neill, L., & O'Neill, M. D. (2017) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2017:17:1 · Cited by 5
Santoro, F., Metzner, A., Scholz, L., Brunetti, N. D., Heeger, C.-H. H., Rillig, A., Reißmann, B., Lemeš, C., Maurer, T., Fink, T., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1384-2 · Cited by 5
Kitamura, Τ., Nakajima, M., Kawamura, I., Ohbe, H., Sasabuchi, Y., Matsui, H., Fushimi, K., Fukamizu, S., & Yasunaga, H. (2020) · Journal of Arrhythmia · doi:10.1002/joa3.12356 · Cited by 5
Groeneveld, S. A., Blom, L. J., van der Heijden, J. F., Loh, P. K. K., & Hassink, R. J. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13359 · Cited by 5
Microbubble-Facilitated Ultrasound Catheter Ablation Causes Microvascular Damage and Fibrosis
Nazer, B., Giraud, D., Zhao, Y. Q., Qi, Y., Mason, O. R., Jones, P. D., Diederich, C. J., Gerstenfeld, E. P., & Lindner, J. R. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.09.007 · Cited by 5
“Radiofrequency (RF) VT ablation is associated with long-term recurrence rates of 12–38% in patients with ischemic cardiomyopathy (Marchlinski et al. 2016; Reddy et al. 2007; Sapp et al. 2016; Tung et al. 2015) and 29–53% in patients with non-ischemic cardiomyopathy (Oloriz et al.”
BackgroundBriceno, D. F., Romero, J. E., Patel, K., Liaqat, W., Zhang, X.-D., Alviz, I., Yang, R., Rodríguez, D., Lakkireddy, D., Rocca, D. G. D., et al. (2020) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-020-00912-w · Cited by 5
“In terms of the control groups, AADs were used in 31% of patients in the VTACH study, 22% in SMS, and 28% in BERLIN VT at 1-year follow-up, while no AADs were used in SMASH VT [5, 6, 14, 15].”
InfluentialKantharia, B. K. (2021) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.15161 · Cited by 5
“difference in mortality was found, meaning ablation procedures did not increase mortality, and fewer patients treated with ablation experienced ICD storms and shocks.(19)”
BackgroundMethodInfluentialCheng, Z., Gao, P., Cheng, K., Chen, T., Deng, H., Chang, B., & Fang, Q. (2012) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2012.00515.x · Cited by 5
Catheter ablation for ventricular tachycardia
Lim, H. S., Singleton, C. B., Alasady, M., & McGavigan, A. D. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2010.02202.x · Cited by 7
The role of ultrasound operation mode for safely interfering in the heart rate
Belassiano, E., Miller, R. J., Hartman, E., OaBrien, W. D., Buiochi, F., & Costa, E. T. (2011) · Pan American Health Care Exchanges · doi:10.1109/pahce.2011.5871899 · Cited by 5
“As for implantable devices, they usually apply shocks to conscious patients, and thus discharges are painful [ 3 ].”
BackgroundSpatiotemporal electrophysiological changes in a murine ablation model
Bernstein, S. A., Duggirala, S., Floberg, M., Elfvendal, P., Kuznekoff, L. M., Lader, J. M., Vásquez, C., & Morley, G. E. (2011) · EP Europace · doi:10.1093/europace/eur168 · Cited by 5
“Complex arrhythmias, such as atrial fibrillation (AF) and ventricular tachycardia, often require extensive lesion sets to achieve acute success.(1) –8 Recurrence rates of these arrhythmias are higher and extensive lesions sets are often pro-arrhythmic.”
BackgroundOutcomes in Women Undergoing Electrophysiological Procedures
Santangeli, P., Biase, L. D., Basile, E., Al‐Ahmad, A., & Natale, A. (2013) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2013.2.1.41 · Cited by 5
Bourke, T., Buch, E. F., Mathuria, N. S., Michowitz, Y., Yu, R., Mandapati, R., Shivkumar, K., & Tung, R. H. (2014) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12477 · Cited by 5
“The major findings of the present study for patients undergoing VT ablation are: (1) The efficiency of ablation is suboptimal as the majority of RF applications do not achieve more than one targeted biophysical parameter; (2) Only one-third of RF applications targeting LPs resulted in complete elimination; (3) Epicard…”
Back, S. H., & Kowey, P. R. (2019) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2018.55.5 · Cited by 5
“the ablation group received ICD therapy (shock or ATP) versus 31% of the control group.(23) Despite the improved rates of ICD therapy, the results of the SMASH-VT trial reinforce the fact that patients with structural heart disease should still receive an ICD given the limited efficacy of ablation.”
ResultCallans, D. J. (2012) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2011.02274.x · Cited by 5
Pham, T., Bennett, R. G., Kanawati, J., Campbell, T. G., Turnbull, S., Thomas, S. P., & Kumar, S. (2022) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-022-01188-y · Cited by 4
Hansen, M. H., Rasmussen, T. B., Risom, S. S., Rosenkranz, S. H., Schou, M., Larroudé, C. E., Gislason, G., Ruwald, A., & Bjerre, J. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae071 · Cited by 5
Actualización en taquicardia ventricular
Fernández‐Armenta, J., Calvo, N., Penela, D., & García‐Bolao, I. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70628-0 · Cited by 4
Quo vadisventricular tachycardia ablation: new horizons and developments
Dickfeld, T. L. (2011) · Expert Review of Medical Devices · doi:10.1586/erd.10.82 · Cited by 4
Furushima, H., Chinushi, M., Iijima, K., Hasegawa, K., Sato, A., Izumi, D., Watanabe, H., & Aizawa, Y. (2011) · EP Europace · doi:10.1093/europace/eur386 · Cited by 4
Ventricular tachycardia ablation and substrate modification in ICD patients with electrical storm
Chen, M. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.20140165 · Cited by 4
Optimal Timing of VT Ablation for Patients with ICD Therapies
Radinovic, A., Baratto, F., & Bella, P. E. D. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01345-7 · Cited by 4
Zhou, S., Wang, R., Seagren, A., Emmert, N., Warren, J. W., MacInnis, P. J., AbdelWahab, A. M., & Sapp, J. L. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183280 · Cited by 4
“Catheter ablation has emerged as an established therapeutic option for the treatment of VAs (Reddy et al., 2007; Kuck et al., 2010; Sapp et al., 2016).”
BackgroundChung, W., Hayase, J. H., Davies, M., Do, D. H., Sorg, J. M., Ajijola, O. A., Buch, E. F., Boyle, N. G., Shivkumar, K., & Bradfield, J. S. (2023) · Heart Rhythm · doi:10.1016/j.hrthm.2023.08.036 · Cited by 4
Sanders, D. J., de Lavallaz, J. D. F., Winterfield, J. R., Santangeli, P., Liang, J. J., Rhodes, P., Ravi, V., Badertscher, P., Mazur, A., Larsen, T. R., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16165 · Cited by 4
Kumar, S., Stevenson, W. G., & John, R. M. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0522-3 · Cited by 4
Ablación de sustrato de las taquicardias ventriculares en pacientes con infarto de miocardio antiguo
Ávila, P., & Arenal, Á. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.08.019 · Cited by 5
“The ablation of CSC and EIC/LP related to clinical or induced VT has been shown to significantly reduce the rate of recurrence of ventricular arrhythmias and to lower the risk of receiving ICD shocks.(8,19,22) On the basis of these data, to simplify the procedure and treat patients showing no electrocardiographic evid…”
BackgroundMapping of ventricular tachycardia in patients with structural heart disease
Mizuno, H. (2014) · Journal of Arrhythmia · doi:10.1016/j.joa.2014.04.015 · Cited by 4
“Catheter ablation is now recognized as the most potent nonpharmacological option to modify the reentrant arrhythmogenic circuit and in some clinical studies has actually been proved to reduce the number of ICD shocks [6,7].”
BackgroundCatheter Ablation of Ventricular Tachycardia in Patients with Post-Infarction Cardiomyopathy
Nazer, B., & Gerstenfeld, E. P. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.4.210 · Cited by 4
Methangkool, E., Howard-Quijano, K. J., & Mahajan, A. (2018) · Advances in Anesthesia · doi:10.1016/j.aan.2018.07.008 · Cited by 4
Ablation Therapy for Refractory Ventricular Arrhythmias
Santangeli, P., & Marchlinski, F. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041818-020033 · Cited by 4
Practical Applications of Electrocardiogram
Lakshmanadoss, U. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77737 · Cited by 4
Sohrabi, C., Ahsan, S., Briasoulis, Α., Androulakis, E. S., Siasos, G., Srinivasan, N. T., & Παπαγεωργίου, Ν. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202047 · Cited by 4
“[64] was established to evaluate whether prophylactic VT ablationwithin 6months after secondary prevention ICD implantation, in patients with spontaneousVT/VF and a history of myocardial infarction, would reduce the incidence of ICD therapy (Table 3).”
BackgroundKatheterablation ventrikulärer Tachykardien bei Patienten mit ischämischer Kardiomyopathie
Bourier, F. J., Busch, S., Sommer, P., Maurer, T., Althoff, T. F., Shin, D., Duncker, D., Johnson, V., Estner, H., Rillig, A., et al. (2022) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s00399-022-00845-z · Cited by 4
Khalil, M., Maraey, A. M., Aglan, A. D., Akintoye, E. O., Salem, M. A., Elzanaty, A., Younes, A. M., Saeyeldin, A. A., Barbhaiya, C. R., & Shokr, M. (2022) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-022-01187-z · Cited by 4
“Catheter ablation has been found to reduce incidence of VT storm, cardiovascular disease–related hospitalization, and implanted cardioverter defibrillator (ICD) shocks when compared to medical therapy alone in patients with ischemic cardiomyopathy and structural heart disease [3, 4].”
BackgroundBiological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics
Lin, Y., Miguel‐dos‐Santos, R., & Cingolani, E. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.05.016 · Cited by 5
Messori, A., Fadda, V., Romeo, M. R., Veneziano, S., & Trippoli, S. (2023) · Cureus · doi:10.7759/cureus.47891 · Cited by 4
Revolutionizing cardiovascular care: the power of histotripsy
Verma, Y., & Arachchige, A. S. P. M. (2024) · Journal of Ultrasound · doi:10.1007/s40477-023-00848-7 · Cited by 4
Schiavone, M., Gasperetti, A., Compagnucci, P., Vogler, J., Laredo, M., Montemerlo, E., Gulletta, S., Breitenstein, A., Ziacchi, M., Martinek, M., et al. (2024) · EP Europace · doi:10.1093/europace/euae066 · Cited by 4
“9 On the other hand, the Substrate Modification in Stable Ventricular Tachycardia in Addition to Implantable Cardioverter Defibrillator Therapy (VTACH) 23 and the Substrate Modification Study (SMS) 24 trials failed to prove a survival benefit, probably due the higher rate of VT episodes in both…”
BackgroundGomes, D., Paiva, M. S., Matos, D. N., Bello, A. R., Rodrigues, G., Carmo, J., Ferreira, J., Costa, F. M., Santos, P. G., Carmo, P., et al. (2024) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.04.002 · Cited by 4
REVIEW: Management of Ventricular Tachycardia in Patients with Structural Heart Disease
Jacobson, J. T., & Weiner, J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00147.x · Cited by 4
Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy
Waldo, A. L. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79277-0 · Cited by 4
Mørk, T. J., Kristensen, J., Gerdes, J. C., Jensen, H. K., Lukáč, P., & Nielsen, J. C. (2014) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2013.877154 · Cited by 4
Fukuzawa, K., Yoshida, A., Kubo, S., Takano, T., Kiuchi, K., Kanda, G., Takami, K., Kumagai, H., Torii, S., Takami, M., et al. (2008) · PubMed · doi:10.24546/81000769 · Cited by 4
Sengupta, J. N., & Abdelhadi, R. H. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283604420 · Cited by 4
“Early ablation was studied in the Substrate mapping and ablation in sinus rhythm to halt ventricular tachycardia (SMASH-VT) study in patients with unstable ventricular tachycardia/ventricular fibrillation, which compared ICD implant with ablation versus ICD implant alone [31].”
MethodCatheter Ablation for Ventricular Tachycardia in Patients with Structural Heart Disease
Markman, T. M., McBride, D. A., & Liang, J. J. (2018) · US Cardiology Review · doi:10.15420/usc.2017:28:3 · Cited by 4
“In the first, the Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) study, relatively lowrisk patients with prior MI who had a history of a single episode of a ventricular arrhythmia or appropriate ICD therapy, but had not received therapy with AADs (class I or III) were randomi…”
MethodPrasitlumkum, N., Navaravong, L., Desai, A., Chewcharat, P., Gandhi, H., Perswani, P., Vallabhajosyula, S., Cheungpasitporn, W., AKOUM, N. W., Jongnarangsin, K., et al. (2022) · Heart Rhythm O2 · doi:10.1016/j.hroo.2022.09.009 · Cited by 4
Self-citationIntegrated Care for Management of Ventricular Arrhythmias
Tung, R. H., & Shivkumar, K. (2013) · Circulation · doi:10.1161/circulationaha.113.001775 · Cited by 4
“In the Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) trial, a nonsignificant trend toward improved mortality was seen in patients randomly assigned to preemptive ablation.(8) With the emerging knowledge of the strong association between implantable cardioverter-defibrillator…”
BackgroundVentricular Tachycardia Ablation
d’Ávila, A., & Singh, S. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.095 · Cited by 4
Nonpharmacologic Treatment of Tachyarrhythmias
Callans, D. J., & Jacobson, J. T. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50026-7 · Cited by 4
Catheter Ablation for Ventricular Tachycardia
John, R. M., & Stevenson, W. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99778-3 · Cited by 4
Calcagno, T., Cesmat, A., Sipko, J., Baranowski, B. J., Bhargava, M., Callahan, T. D., Chung, M. K., Dresing, T., Hussein, A. A., Irefin, S. A., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.05.063 · Cited by 3
Tran, H. H.-V., Aguilar, I. K., Thu, A., Mehta, K. A., Shaji, M. N., Mahadevaiah, A., Twayana, A. R., Weissman, S. I., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000990 · Cited by 3
Falconer, D., Salih, A. A., Captur, G., SCHILLING, R. J., Lambiase, P. D., Παπαγεωργίου, Ν., & Providencia, R. A. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf171 · Cited by 3
“24,25,28,30,32,35 There was a significant reduction in therapies: 102 in the ablation group compared with 150 in the control group [29.7% vs. 41.4%; RR 0.74, 95%CI 0.61– 0.89; P = 0.02, I 2 = 32.5%; NNT = 8.5 (95% CI 5.3–20.9) patients to prevent one ICD therapy] ( Figure 4C ).”
InfluentialNaksuk, N., DeSimone, C. V., Kapa, S., & Asirvatham, S. J. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2013.12.046 · Cited by 3
Management of Pace-Terminated Ventricular Arrhythmias
Pokorney, S. D., & Al‐Khatib, S. M. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.05.009 · Cited by 3
Emerging Tools and Techniques for Catheter Ablation of Cardiac Arrhythmias: A 2024 Update
Aryana, A., & d’Ávila, A. (2024) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2024.15019 · Cited by 3
“…decades after its publication by Reddy et al., the Sub-strate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) trial 37 —an elegant and randomized trial of “prophylactic” substrate-based VT ablation shown to reduce the incidence of defibrillator therapies in…”
BackgroundActive Arrhythmia Pattern: A Novel Predictor of ICD Shocks—A Subanalysis From the PARTITA Study
Radinovic, A., Giacopelli, D., Bisceglia, C., Paglino, G., Gargaro, A., & Bella, P. E. D. (2024) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.123.012523 · Cited by 3
Dennis, A. S. C., Orini, M., Hesselkilde, E. M., Saljic, A., Linz, B. M., Sattler, S. M., Williams, J., Tfelt‐Hansen, J., Jespersen, T., CHOW, A. W. C., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.07.028 · Cited by 3
Trivedi, S. J., Bennett, R. G., Byth, K., Campbell, T. G., Turnbull, S., Stefani, L. D., Kumar, S., & Thomas, L. (2025) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2025.05.004 · Cited by 3
Management of ventricular arrhythmias in structural heart disease
Jacobson, J. T., Iwai, S., & Aronow, W. S. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1045816 · Cited by 4
“As SMASH-VT suggests, ablation of VT has the additional effect of decreasing ICD therapies for VF as well [105], likely explained by the fact that many VF episodes begin as VT, but also likely due to the extensive substrate ablation.”
BackgroundEvolution of ventricular tachycardia ablation in structural heart disease
Tung, R. H. (2014) · Journal of Arrhythmia · doi:10.1016/j.joa.2014.04.005 · Cited by 3
““T-shaped” lesions were implemented in SMASH-VT at the border zone of a good pacemap site, with perpendicular linear ablation into scar to potentially ablate deeper in a conducting channel [75].”
BackgroundMethodKomaki, H., Nakashima, T., & Minatoguchi, S. (2018) · Cardiology in the Young · doi:10.1017/s1047951118000471 · Cited by 3
“Appropriate ablation therapy enables these patients to be free of anti-arrhythmic drugs and reduces the need for an implantable cardioverter-defibrillator.(11) Further prospective studies may show that it is possible to use ablation as a sole therapy.”
Lane, J. D., Cannie, D. E., Volkova, E., Graham, A. J., CHOW, A. W. C., Earley, M. J., Hunter, R. J., Khan, F. Z., Lambiase, P. D., SCHILLING, R. J., et al. (2018) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13502 · Cited by 3
Sultan, A., Bellmann, B., Lüker, J., Plenge, T., van den Bruck, J., Filipovic, K., Erlhöfer, S., Kuffer, L., Arica, Z., & Steven, D. (2019) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-019-00530-1 · Cited by 3
Malik, A. H., & Aronow, W. S. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000928 · Cited by 3
Adlan, A., Arujuna, A., Dowd, R. P., Hayat, S. A., Panikker, S., Foster, W., Yusuf, S., Umar, F., Lellouche, N., Osman, F., et al. (2019) · Open Heart · doi:10.1136/openhrt-2018-000996 · Cited by 3
Nonpharmacologic Treatment of Tachyarrhythmias
Callans, D. J., & Anter, E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00021-7 · Cited by 3
Kheiri, B., Simpson, T. F., & Nazer, B. (2020) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14111 · Cited by 3
Utility of Ischemia Testing Prior to Ablation for Sustained Monomorphic Ventricular Tachycardia.
Mehta, N. K., Schumann, C. L., Davogustto, G., Cluckey, A., Harmon, E., France, J., Mangrum, J. M., Mason, P. K., Mazimba, S., Malhotra, R., et al. (2022) · PubMed Central · doi:10.19102/icrm.2022.130301 · Cited by 3
“The significant predictors of VT recurrence following ablation in our study were (1) number of failed antiarrhythmic drugs, (2) type of cardiomyopathy, (3) sex, and (4) pre-ablation CMR.”
Contemporary Management of Complex Ventricular Arrhythmias
Wiles, B. M., Li, A. C., Waight, M. C., & SABA, M. M. (2022) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2021.66 · Cited by 5
Intensive Care Society State of the Art 2016 Abstracts
Auzinger, G., Best, T., Gelandt, E., Hurst, T., Kakar, V., Loveridge, R., Morgan, L., Nevett, J., Park, C., Patel, S., et al. (2016) · Journal of the Intensive Care Society · doi:10.1177/1751143717708966 · Cited by 4
Cardelli, L. S., BARBATO, G., Carinci, V., Pergolini, F., Leci, E., & Casella, G. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101349 · Cited by 3
Dhruva, S. S., Zhang, S., Chen, J., Noseworthy, P. A., Doshi, A. A., Agboola, K. M., Herrin, J. S., Jiang, G., Yu, Y., Cafri, G., et al. (2023) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-023-01496-x · Cited by 3
“Additionally, some clinical trials of VT have relied only on a history of MI [22].”
BackgroundDoldi, F., Geßler, N., Anwar, O., Kahle, A., Scherschel, K., Rath, B., Köbe, J., Lange, P. S., Frommeyer, G., Metzner, A., et al. (2024) · Thrombosis and Haemostasis · doi:10.1055/s-0044-1785519 · Cited by 3
Sex, Race, and Rural-Urban Disparities in Ventricular Tachycardia Ablations
Tang, A. B., Akinrimisi, O. P., & Ziaeian, B. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.05.033 · Cited by 3
Pitzus, A., Baldazzi, G., Orrù, M., Raffo, L., Viola, G., Djurić, P. M., & Pani, D. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.106844 · Cited by 3
Margolis, G., Nov, C., Kazatsker, M., Kobo, O. M., Roguin, A., & Leshem‐Rubinow, E. (2024) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.15080 · Cited by 3
Can ICD Electrograms Help Ventricular Tachycardia Ablation?
Ibáñez, J. L., Ortiz, M., Fernandez, F., Martínez-Alday, J. D., Font, E. R., Moreno, J., López, M. Á., Martí‐Almor, J., López‐Gil, M., Medina, D. G., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.104 · Cited by 3
Metadata
- Authors
- Reddy, V. Y., Reynolds, M. R., Neuzil, P., Richardson, A. W., Taborsky, M., Jongnarangsin, K., Kralovec, S., Sediva, L., Ruskin, J. N., & Josephson, M. E.
- Affiliations
- Massachusetts General Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-12-27
- Volume
- 357
- Issue
- 26
- Pages
- 2657-2665
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2390777
- OpenAlex
- W2139803224
- Cited by
- 959
- References
- 28
- Citations by year
- 2026: 39 · 2025: 42 · 2024: 47 · 2023: 43 · 2022: 53 · 2021: 45 · 2020: 54 · 2019: 62 · 2018: 53 · 2017: 63 · 2016: 40 · 2015: 59 · 2014: 46 · 2013: 56 · 2012: 48
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23 HL 68064, K23HL077171, K23HL068064)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- implantable cardioverter-defibrillator, ventricular tachyarrhythmia, myocardial infarction, sudden cardiac death, radiofrequency ablation, substrate-based ablation, myocardial scar, ICD shocks, secondary prevention
- MeSH terms
- Aged, Electric Countershock, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Ventricular Fibrillation, Multivariate Analysis, Death, Sudden, Cardiac, Catheter Ablation, Defibrillators, Implantable, Tachycardia, Ventricular, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.